PRINCETON, NJ, KayoThera, an early-stage therapeutics company, has closed an $8 million Series A round of financing led by Accelerator Life Science Partners.
KayoThera, an early-stage therapeutics company developing novel cancer immunotherapies, announces the closing of an $8 million Series A round of financing. The financing was led by Accelerator Life Science Partners with participation from BioAdvance and 7G Bioventures.
KayoThera is an early-stage therapeutics company focused on the development of a new class of cancer immunotherapeutics. KayoThera is developing therapies to treat late-stage and metastatic cancers including breast, lung, pancreatic, colorectal, brain, and kidney cancers.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
